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Insights into the catalytic mechanism of human sEH phosphatase
by site-directed mutagenesis and LC-MS/MS analysis
Abstract
We have recently reported that human soluble epoxide hydrolase (sEH) is a bifunctional enzyme with a
novel phosphatase enzymatic activity. Based on a structural relationship with other members of the
haloacid dehalogenase superfamily, the sEH N-terminal phosphatase domain revealed four conserved
sequence motifs, including the proposed catalytic nucleophile D9, and several other residues potentially
implicated in substrate turnover and/or Mg(2+) binding. To enlighten the catalytic mechanism of
dephosphorylation, we constructed sEH phosphatase active-site mutants by site-directed mutagenesis. A
total of 18 mutants were constructed and recombinantly expressed in Escherichia coli as soluble
proteins, purified to homogeneity and subsequently analysed for their kinetic parameters. A replacement
of residues D9, K160, D184 or N189 resulted in a complete loss of phosphatase activity, consistent with
an essential function for catalysis. In contrast, a substitution of D11, T123, N124 and D185 leads to sEH
mutant proteins with altered kinetic properties. We further provide evidence of the formation of an
acylphosphate intermediate on D9 by liquid chromatography-tandem mass spectrometry based on the
detection of homoserine after NaBH(4) reduction of the phosphorylated enzyme, which identifies D9 as
the catalytic nucleophile. Surprisingly, we could only show such homoserine formation using the D11N
mutant, which strongly suggests D11 to be involved in the acylphosphate hydrolysis. In the D11 mutant,
the second catalytic step becomes rate limiting, which then allows trapping of the labile intermediate.
Substrate turnover in the presence of (18)H(2)O revealed that the nucleophilic attack during the second
reaction step occurs at the acylphosphate phosphorous. Based on these findings, we propose a two-step
catalytic mechanism of dephosphorylation that involves the phosphate substrate hydrolysis by
nucleophilic attack by the catalytic nucleophile D9 followed by hydrolysis of the acylphosphate enzyme
intermediate supported by D11.
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Summary
We have recently reported that human soluble epoxide hydrolase (sEH) is a bifunctional enzyme with
a novel phosphatase enzymatic activity. Based on a structural relationship with other members of the
haloacid dehalogenase (HAD) superfamily, the sEH N-terminal phosphatase domain revealed four
conserved sequence motifs, including the proposed catalytic nucleophile D9, and several other
residues potentially implicated in substrate turnover and/or Mg2+  binding. To enlighten the catalytic
mechanism of dephosphorylation we constructed sEH phosphatase active site mutants by site directed
mutagenesis. A total of 18 mutants were constructed and recombinantly expressed in Escherichia coli
as soluble proteins, purified to homogeneity and subsequently analysed for their kinetic parameters. A
replacement of residues D9, K160, D184 or N189 resulted in a complete loss of phosphatase activity,
consistent with an essential function for catalysis. In contrast, a substitution of D11, T123, N124 and
D185 lead to sEH mutant proteins with altered kinetic properties. We further provide evidence of the
formation of an acylphosphate intermediate on D9 by LC-MS/MS based on the detection of
homoserine after NaBH4 reduction of the phosphorylated enzyme, which identifies D9 as the catalytic
nucleophile. Surprisingly, we could only show such homoserine formation using the D11N mutant,
which strongly suggests D11 to be involved in the acylphosphate hydrolysis. In the D11 mutant the
second catalytic step becomes rate limiting, which then allows trapping of the labile intermediate.
Substrate turnover in the presence of 18H2O revealed that the nucleophilic attack during the second
reaction step occurs at the acylphosphate phosphorous. Based on these findings we propose a two step
catalytic mechanism of dephosphorylation which involves the phosphate substrate hydrolysis by
nucleophilic attack by the catalytic nucleophile D9 followed by hydrolysis of the acylphosphate
enzyme intermediate supported by D11.
Introduction
Mammalian soluble epoxide hydrolase (sEH, EC 3.1.3.76; EC 3.3.2.10) is a homodimeric enzyme
that combines two separate catalytic domains in each monomer. A novel phosphatase activity is
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located in the N-terminal domain, whereas the C-terminal domain functions as an epoxide hydrolase
(Figure 1). Most of the established sEH functions are currently assigned to the epoxide hydrolase
activity. Apart from its classic role in detoxification processes involving potentially harmful epoxides1,
the main function of sEH certainly is the metabolism of endogenous arachidonic acid derived
signalling molecules like epoxyeicosatrienoic acids (EETs) to the corresponding diols (DHETs)2 ;  3.
Hence the sEH has evolved as a target for the therapy of hypertension4; 5  and inflammatory diseases6; 7;
8, and has of late attracted attention as regards a novel treatment of pain, diabetes and stroke9; 10; 11.
Our group as well as others have recently discovered that the sEH N-terminal domain displays a
novel phosphatase activity12; 13. Phosphatases are enzymes that are able to catalyse the hydrolysis of a
large variety of phosphate monoesters using different catalytic strategies. Substrates range from
phosphorylated proteins14; 15; 16  and nucleic acid to a broad range of small phosphorylated
metabolites17. The sEH phosphatase has so far been shown to accept the generic substrate 4-NPP,
some lipid phosphates13; 18, as well as isoprenoid phosphates19; 20, possibly connecting the sEH
phosphatase to cholesterol biosynthesis or lipid metabolism. The physiological role of this
phosphatase activity remains uncertain to date, but the bifunctional character of human sEH implies
that the sEH phosphatase may have a regulatory function in connection with the epoxide hydrolase
activity.
Based on structural similarities, both domains of mammalian sEH are grouped within large and
separate superfamilies of hydrolases. While the C-terminal epoxide hydrolase domain adopts a α/β-
hydrolase fold21; 22; 23, its smaller N-terminal domain belongs to a distinct family of haloacid
dehalogenases (HAD), largely composed of phosphatases, dehalogenases, phosphotransferases, and
other hydrolases24; 25. Members of the HAD family are ubiquitously expressed in prokaryotes and
eukaryotes, and they cover an exceptionally broad catalytic spectrum in metabolism, membrane
transport, signal transduction or nucleic acid repair17; 26; 27. Despite an overall low sequence similarity,
all enzymes of the HAD superfamily possess a structurally conserved rossmannoid α,β-core domain
containing four loops that represent the catalytic scaffold. As displayed in figure 2, each of the four
loops contains a characteristic sequence motif; in all HADs members the catalytic Asp nucleophile
located in loop 1 is most highly conserved. Many HADs contain an additional aspartic acid residue
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two positions downstream of the Asp nucleophile in loop 1 that was suggested to function as a general
acid/base in the catalytic cycle of phosphotransferases and phosphatases17; 28. The loops 2 and 3
position the substrate phosphoryl binding residues Ser/Thr and Lys/Arg, whereas loop 4 either
contains the Mg2+ binding pocket formed by two aspartic acids in phosphatases, or two Ser residues
that stabilise the nucleophile and/or water in the dehalogenases29; 30; 31.
Furthermore all HAD enzymes are grouped within three subfamilies I-III by virtue of the presence
and location of an additional cap domain that is implicated in solvent protection of the active site as
well as substrate selectivity32. Class I HADs such as phosphonatase, phosphoserine phosphatase or the
sEH phosphatase (See figure 1) contain an insertion between loop 1 and 2 of the core domain, whereas
a larger cap domain is inserted between loop 2 and 3 of class II HAD members33; 34. The class III HAD
subfamily members do not provide a cap domain, thus being better suited to accept large substrates
such as proteins or t-RNA32; 35.
The three dimensional structure of human soluble epoxide hydrolase has recently been solved with
a resolution of 2.6 Å36, revealing a hexacoordinated Mg2+ bound in the phosphatase active site at the
bottom of a 15 Å deep pocket as well as a product complex with HPO42-. The enzyme shows a domain
swapped architecture similar to murine sEH37, where the phosphatase domain of one homodimer
interacts with the epoxide hydrolase domain of the other. In line with our previous analysis the human
sEH crystal structure displays several residues potentially composing the sEH phosphatase active site.
Based on the homology with other HADs a two step mechanism for the dephosphorylation reaction
has been proposed29; 31; 36. The first step comprises of a nucleophilic attack by the D9 on the substrate
phosphoester group and protonation of the leaving group. In a second step the phosphoenzyme
intermediate hydrolyses via a nucleophilic attack by an activated water molecule. This proposed
mechanism of dephosphorylation is further supported by two computational studies38; 39, where the
authors investigated the first and second step of the dephosphorylation reaction using quantum
mechanical/molecular dynamics calculations and describe two highly efficient water bridge mediated
proton shuttles during phosphoryl transfer in their model. The investigations proposing such
mechanism are conclusive in describing the dephosphorylation pathway, but the specific site of
phosphorylation as the intermediate step in the dephosphorylation reaction has not been shown
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experimentally. We now present a biochemical analysis of human sEH phosphatase catalytic
mechanism. We selected candidate active site amino acid residues of the human sEH phosphatase and
investigated their role in catalysis by site directed mutagenesis. Moreover we provide evidence of the
formation of the D9 acylphosphate intermediate and for an involvement of D11 in the hydrolysis of
the acylphosphate by tandem mass spectrometry analysis of the phosphorylated and derivatised
enzyme. Finally, hydrolysis of the acylphosphate in the presence of 18H2O reveals the site of the
nucleophilic attack during the second step of the reaction. These combined analyses give a detailed
insight into sEH catalysed dephosphorylation reactions.
Results
Selection of candidate phosphatase active site amino acids
On the basis of structural similarities between the sEH and other members of the HAD superfamily
as described in detail earlier12, we predicted candidate catalytic amino acids in the active site of the
sEH phosphatase domain to be crucial to its catalytic activity. The sEH phosphatase has four
conserved sequence motifs as highlighted in figure 2. Sequence motif I (DXDXT/V) includes the
potential catalytic nucleophile D9, a position which is highly conserved among all HAD members.
Motif I also displays a second aspartic acid residue (D11 in the case of the sEH phosphatase) which is
assumed to act as a general acid/base catalyst in related HAD phosphatases such as the phosphoserine
phosphatase from Methanococcus janaschii28. All HAD members contain a serine or threonine residue
in a conserved position in motif II as well as a basic amino acid residue in motif III (T123 and K160 in
the sEH phosphatase), both of which are supposed to hydrogen bond to the negatively charged
phosphate substrate. Furthermore, N124 was selected as a candidate member of the sEH phosphatase
active site due to its spatial orientation observed in the active site of the murine sEH crystal structure37.
The least conserved motif IV (G/SDXXN/TD) contains two aspartic acids that are either vicinal (like
in the sEH) or separated by three or four amino acids and both are implicated in binding the divalent
cation within the active site26; 28. Interestingly, in haloacid dehalogenases - as an exception - the two
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vicinal aspartates are replaced by serines to function in stabilisation of the catalytic nucleophile
(Haloacid dehalogenases do not have a cation in the active site)30. Finally, N189 which resembles the
conserved position of the second aspartic acid residue in loop 4 in the primary sequence of other
phosphatases and which is further orientated towards the active site was selected for amino acid
exchange.
Construction of sEH phosphatase active site mutants
To investigate whether these candidate amino acids are directly involved in catalysis, the residues
in question were substituted by site directed mutagenesis of an expression construct encoding the N-
terminal domain of human soluble epoxide hydrolase including a C-terminal His6-Tag (Figure 3). At
least two alternative amino acids, either alanine or an amino acid structurally similar to that in the WT
enzyme - to remove the side chain functionality, yet to maintain structural integrity of the mutant
protein - were introduced for each candidate amino acid. We further designed the primers for site
specific mutagenesis to contain new or delete existing restriction sites for easier identification. The
correct coding sequences were confirmed by DNA sequencing. In total 18 different recombinant
clones were constructed encoding mutant sEH phosphatase proteins with a single amino acid residue
substitution for the putative candidates of the sEH phosphatase active site.
Expression and purification of recombinant sEH phosphatase
Transformation of E. coli BL21-AI with the WT or mutant sEH vector constructs and induction of
protein expression with 100 µM L-arabinose resulted in the production of recombinant 24 kDa
proteins corresponding to the phosphatase domain of human sEH with very similar expression levels
of approximately 5 % of the soluble cellular protein content for each of the different proteins. Due to
the His6-tag (The His6-tag was shown previously not to interfere with the catalytic activity of the
enzyme12) the sEH proteins were purified in a two step procedure using metal chelate affinity
chromatography followed by size exclusion chromatography. As an example, figure 3 gives an
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indication of the level of purity for 4 of the 18 recombinant proteins. The remaining mutants were
similarly purified to apparent homogeneity. None of the active site mutants formed insoluble protein
due to misfolding or aggregation, and all proteins showed similar behaviour during the two step
purification procedure, suggesting that all active site mutants were folded correctly.
Characterisation of sEH phosphatase mutants by site directed mutagenesis
WT and mutant sEH proteins were analysed in a first screening assay for their biochemical
properties using a photometric assay to scan for product formation from the generic substrate 4-NPP.
Those mutants with detectable enzyme activity were then further evaluated in kinetic activity
measurements. All experiments were performed in triplicate from three separately produced and
purified protein batches. The sEH WT phosphatase hydrolysed 4-NPP with a turnover number of
0.033 x s-1 and a Km of 1.04 mM, these values are of the same order of magnitude as previously found
in the sEH phosphatase12. Table 1 summarises the kinetic parameters derived from the analysis of the
sEH mutant proteins.
Several amino acid exchanges lead to completely inactive enzyme, consistent with an important
function for catalysis. Both active site mutations D9A and D9N within loop I resulted in a complete
loss of activity against 4-NPP, demonstrating D9 to be crucial to sEH phosphatase activity. Also an
exchange of the amino acids K160 (motif III) as well as D184 and N189 placed within motif IV with
non functional amino acid residues resulted in a complete loss of enzymatic activity, proving their
essential function for catalysis.
In contrast, some active site residue exchanges resulted in mutant proteins with retained activity.
We found in our analysis that the D11 active site mutants are either inactive (D11A) or strongly
reduced (D11N) in their catalytic activity, with a significant twofold decrease in Km (P-value 0.014,
two sided students t-test) and a nine fold reduction of kcat compared to the WT enzyme. A substitution
of D185 with alanine resulted in a completely inactive sEH phosphatase which is in line with the
predicted role of D185 in coordinating the Mg2+ cation. Instead, a replacement with asparagine only
reduces Vmax of the enzyme to 35% while leaving the Km unchanged. In order to test whether a
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replacement of aspartic acid by an asparagine results in an initially inactive enzyme that slowly
regenerates itself by deamination we subjected the sEH phosphatase mutant D185 to tryptic digest and
analysed the resulting peptides by tandem mass spectrometry. However, no self activation of the
respective D185N mutant was detected after incubation of the purified protein fraction at 4°C for two
weeks, followed by ESI-MS analysis of the tryptic peptides. A mass shift of 1 amu - corresponding to
the still present point mutation D185N - is clearly detectable in the fragment ion spectrum of the
mutant protein (Figure 4). A deamination of asparagine instead would have resulted in a fragment ion
spectrum identical to the WT peptide.
Proteins with significantly reduced catalytic activity compared to the WT type enzyme also
resulted from a substitution of T123A and T123N (T123V proved to be inactive) and both N124
mutations, whereas only the N124D mutant showed a 2.5fold increase in Km (P-value 0.016, two sided
students t-test).
Determination of the site of sEH phosphorylation by LC-MS/MS
In order to identify the specific site of phosphorylation during the catalytic cycle of the enzyme, we
subjected sEH tryptic peptides - after phosphorylation of the enzyme with its substrates 4-NPP and
reduction with sodium borohydride - to reversed phase liquid chromatography followed by tandem
mass spectrometry analyses. Measurements were performed in an MRM initiated detection and
sequencing (MIDAS) mode to identify and analyse specific peptides, mutations or modifications40; 41.
Figure 5 (a) presents the average peptide sequence coverage of the sEH phosphatase, using a set of
MRM transitions for targeted tryptic sEH peptides. Tryptic peptides derived from the WT sEH as well
as the D9N and D11N, T123A and D185N mutant proteins were analysed in quintuplicate by LC-
MS/MS and product ion spectra were matched against a protein databank using the Mascot search
engine. We detected the specific homoserine formation after reduction with borohydride in the D11N
mutant only, but not in the WT enzyme or the other mutant proteins. Figure 5 shows the total ion
chromatograms of the D11N mutant (b) and WT sEH (c) peptide separation, with an additional peak at
retention time 32.02 min that only appears in the D11N mutant after reduction. Figure 5(d) - (e) show
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the fragment spectra of the precursor ions 1050.62+ (corresponding to the WT sEH peptide containing
D9) and 1043.12+ (corresponding to the D11N peptide with an additional D9hS exchange) which
proves D9 to be the site of phosphorylation during the catalytic cycle. Fragment ions of the y-ion series
from 9-14 identify both sEH peptides and diagnostic fragments to identify the D9hS mutated peptides
are marked with arrows.
Determination of the site of sEH dephosphorylation by LC-MS/MS
We further studied the hydrolysis of the sEH WT acylphosphate by 18O incorporation. Subsequent
analysis of the resulting tryptic peptides after phosphorylation of the WT sEH with 4-NPP in the
presence of 18H2O by LC-MS/MS revealed the nucleophilic attack to occur at the phosphorous,
because no incorporation of 18O was detectable in the corresponding peptides.
Discussion
Following site directed mutagenesis the resulting WT and mutant sEH proteins were analysed for
their kinetic properties to further characterise the catalytic mechanism of dephosphorylation. Several
amino acid exchanges led to a completely inactive enzyme, which is largely consistent with the
interactions of active site residues observed in the human sEH crystal structure36. Figure 1(c) presents
the structure model of the human sEH phosphatase active site containing the Mg2+ and HPO42-. The 3D
structure shows the magnesium to be nearly octahedrally coordinated by D9, D185, the backbone
oxygen of D11, two water molecules and the phosphate oxygen. This phosphate forms several
hydrogen bond interactions with K160, T123, the backbone NH group of D11, as well as the backbone
NH group and carbonyl oxygen of N124.
The exchange of D9 in motif I resulted in inactive protein in the case of any amino acid, which
supports D9 to be the catalytic nucleophile of the sEH phosphatase. This is much in line with our
previous structural alignment and some investigations that analysed the relation of sEH to other
members of the HAD family12; 26. However up to this point a direct phosphorylation of D9 during the
AC
CE
PT
ED
 M
AN
US
CR
IPT
ACCEPTED MANUSCRIPT
10
catalytic cycle of the enzyme had not been shown. Using a precursor ion scan for m/z 79 in the
negative ion mode (representing a loss of phosphate), sEH samples were first analysed by tandem
mass spectrometry to specifically detect phosphorylated peptides. But, due to an apparent instability in
the resulting D9 acylphosphate a direct identification of the phosphorylated intermediate by LC-
MS/MS proved to be difficult, as it has been described for the detection of aspartylphosphates in
particular42; 43. In an effort to circumvent the lability of the generated acylphosphate we chose to trap
the intermediate by derivatisation with sodium borohydride44; 45. A selective reduction of
aspartylphosphate leads to the corresponding alcohol homoserine which can easily be distinguished
from the WT peptide by a mass shift of 15 amu of the mutated peptide precursor ion mass. The
MS/MS fragment spectra further show the specific site of modification in the sEH peptide, which
proves D9 to be the catalytic nucleophile of the sEH active site (Figure 5).
The nature of the amino acid two positions downstream of the catalytic nucleophile in loop 1 and
its function as a general acid/base catalyst is a matter for debate, because in some HADs this aspartate
is replaced by threonine, tyrosine or alanine17 and therefore not absolutely required. 
 
Our results prove
an involvement of D11 in the dephosphorylation reaction. The mutagenesis experiments show that the
D11 active site mutants are either inactive or strongly reduced in their catalytic activity with a
significant reduction in Km. This would support the hypothesis that the D11 carboxylic acid side chain
is directly involved in catalysis, which would explain the strongly reduced kcat. This finding is
particularly interesting because according to the human sEH crystal structure the D11 side chain is
directed away from the reaction centre and therefore this scenario is only possible if D11 were able to
undergo a substrate induced conformational change like has been observed for a homologous
phosphoglucomutase46; 47. D11 interacts with the Mg2+ ion and the substrate phosphate oxygen only
through its backbone oxygen and NH groups. D11 further donates a hydrogen bond to an Mg2+
coordinating water molecule and the side chain of R99 which resides in the cap domain. Because the
cap domain is implicated in substrate recognition17; 33 and solvent exclusion33, such a substrate induced
fit by a rather flexible cap domain seems to be a possible explanation. The slight differences that are
seen by superimposition of the human and murine phosphatase domains are also mainly confined to
some loops in the cap domain. Therefore the human sEH crystal structure in complex with a HPO42-
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ion from solvent buffer may more likely mimic the enzyme product rather than the enzyme substrate
complex. Similarly as has been proposed for the phosphoserine phosphatase (PSP) from
Methanococcus janaschii28 D11 could protonate the substrate leaving group of the phosphate substrate
in the first step and deprotonate the acylphosphate attacking solvent water in the second step in
acid/base catalysed manner. A replacement of the D11 side chain by asparagine or alanine most likely
leads to reduced or no water activation and conformational changes in the coordinating Mg2+ metal
sphere. Because DeVivo et al.38; 39 did not include the D11 side chain in their model for quantum
mechanical/molecular dynamics calculations the authors also would not support such a mechanism.
Strong support for this is found in our LC-MS/MS analysis, because only in the D11N mutant, but
not the D9N mutant or the WT enzyme we were able to detect the very specific homoserine formation
after reduction with borohydride. This further underlines a role of D11 in the second step of the
catalytic process. In an enzymatic reaction involving a covalent intermediate the Michaelis constant
Km resolves to Km = KD x k2/(k1+k2) (where k1 describes the velocity of a formation of the
acylphosphate and release of substrate, whereas k2 describes the release of phosphate) and only in the
case of k1 being orders of magnitudes smaller than k2, k1 becomes negligible, Km equals KD and
therefore KD can be interpreted as a measure for enzyme affinity. In the case of the WT phosphatase
the first step (k1) of the reaction can be considered the rate limiting step38, therefore an active site
mutation affecting the first step of the reaction cycle would change kcat but have little impact on Km. In
the case of k2 being significantly smaller than k1 instead, Km resolves to Km = KD x k2/k1, therefore a
mutation that strongly effects k2 (such that the second reaction step becomes rate limiting) would
indeed decrease Km, as has been seen in the D11N mutant. It is intriguing to speculate that the D11N
mutant resembles a mutant phosphatase where the second step of the catalytic cycle is blocked and the
remaining activity represents the spontaneous hydrolysis of the acylphosphate. In the WT phosphatase
the homoserine formation most likely competes with the rapid hydrolysis of the acylphosphate
facilitated by D11, and therefore the homoserine formation is only detectable in the mutated D11
protein where the hydrolysis of the acyl intermediate is slowed down accordingly. Moreover, a Vmax
smaller than that of the D11 mutant should then indicate an impaired first reaction step for those
mutant proteins. Because the D11A is completely inactive an involvement of D11 in the acid catalysed
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substrate release is likely, though hard to resolve. The exchange against alanine might impair the Mg2+
and phosphate coordination sphere and it probably strongly interferes with the positioning of the cap
domain through interruption of the hydrogen bridges to R99 and the Mg2+ coordinating water, which
might explain the loss of activity. Although the D11N should not anymore be able to activate a water
molecule or directly protonate the substrate leaving group, a change in k1 would not be observed once
k2 becomes rate limiting. Therefore we conclude an involvement of D11 at least in the second step of
the dephosphorylation reaction.
We further analysed the dephosphorylation reaction by 18O incorporation. During the second step
of the reaction cycle the covalent enzyme acylphosphate intermediate is hydrolysed via a nucleophilic
attack by an activated water molecule either on the phosphorus atom of the phosphate moiety or - like
in Mg2+ free haloacid deaholgenases - at the aspartate carbonyl. Hydrolysis of the acylphosphate in the
presence of 18H2O would lead to an incorporation of 18O into the phosphate leaving group, if the site of
attack were the phosphorous. In contrast, if an activated water were to bind to the aspartic acid
carbonyl, an incorporation of 18O into the D9 containing sEH peptide would be detectable due to a
mass shift of 2 or 4 amu respective to one or two catalytic turnovers. Using our methods such mass
difference can be significantly detected, because we were able to detect the amino acid exchange of
aspartic acid against asparagine resulting in a mass difference of only 1 amu. Subsequent analysis of
the resulting peptides after phosphorylation of the WT sEH with 4-NPP in the presence of 18H2O by
LC-MS/MS revealed the nucleophilic attack to occur at the phosphorous, because no incorporation of
18O was detectable in the corresponding peptides. This indeed is in line with the mechanisms proposed
for other phosphatases.
Mutant proteins with significantly reduced catalytic activity resulted from the substitution of T123
and N124 residues within motif II. These exchanges reduced Vmax by a factor of 15 and 30
respectively, while only varying Km by a factor not greater than two. As described above, those mutant
phosphatases that show a Vmax smaller than that of the D11N mutant, while having an increased or
unchanged Km, likely show an altered first and second step of the reaction cycle, which implicates
both active site residues in substrate positioning and phosphate substrate turnover. The T123V mutant
is probably structurally slightly impaired which might affect the phosphate positioning, whereas the
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effect of a substitution with alanine or asparagine might be compensated by other components of the
active site or a water molecule, seeing as both the phosphate substrate and the divalent cation are
multiply coordinated. The same accounts for N124, forming hydrogen bonds with the phosphate
oxygen through its backbone NH and CO groups, and therefore an exchange of the amino acid side
chain does not prove N124 to be essential but rather leads to an impaired backbone conformation.
Due to the charged character of the K160 side chain in motif III and thus strong interaction with the
substrate phosphate moiety, the enzyme looses all activity after exchange of K160 against any amino
acid (including the other basic amino acid arginine) proving its vital role in substrate positioning
within the active site.
Finally, in motif IV an exchange of amino acid D184 with non functional amino acid residues
resulted in a complete loss of enzymatic activity, confirming its essential function for catalysis. In the
three dimensional structure D184 forms hydrogen bridges to K160 and the solvent water which
coordinates the divalent Mg2+ cation. Both interactions are needed to shield the charge of the
phosphoryl group while being attacked by the catalytic nucleophile, or the enzyme loses its activity.
The substitution of D185 with alanine resulted in a completely inactive sEH phosphatase, while a
replacement with asparagine resulted in still active enzyme. One possible explanation might be that a
replacement of aspartic acid by an asparagine results in an initially inactive enzyme that slowly
regenerates itself after a period of time to active enzyme. Such regeneration has been shown for the
epoxide hydrolase from Aspergillis niger48 or a glutamate dehydrogenase49; 50 after replacement of the
catalytic nucleophile D to N. To take such possible self-regeneration by deamination into
consideration we analysed tryptic peptides derived from the sEH phosphatase mutant D185 by mass
spectrometry, but no self activation of the respective D185N mutant was detected by ESI-MS analysis
of the tryptic peptides. An exchange of aspartic acid against the structurally similar but uncharged
asparagine probably interferes with the metal coordination sphere and therefore alters the enzyme
activity in the first step of catalysis.  
An exchange of N189 with non functional amino acid residues resulted in the complete loss of
enzymatic activity, indicating an important function of this residue for catalysis. The introduction of
an additional charge by an exchange against aspartic acid probably increases the electrostatic repulsion
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of then three aspartates, which interferes with the enzyme activity. A mutation of N189 which is within
hydrogen bonding distance to the side chain of D184 might lead to a conformational change effecting
D184 that forms a hydrogen bridge with one Mg2+coordinating solvent water and further stabilises
K160, which in turn strongly interferes with catalytic activity. It is unique to sEH, that obviously all
three amino acid residues from the conserved motif in the metal binding loop IV are needed to
stabilise the active site, whereas generally in HADs only two aspartic acid residues seem critical in
loop IV26.
These combined analyses lead us to present the following reaction mechanism related to other
members of the HAD family30; 51; 52. As illustrated in figure 6 the first step of the catalytic cycle
consists of a nucleophilic attack by the D9 on the substrate phosphoester group under formation of
phosphoenzyme intermediate, supported by the absolute requirement of D9 for activity and the D9
phosphorylation demonstrated by LC-MS/MS. The protonation of the substrate leaving group is likely
provided by the side chain of D11 after a substrate induced rearrangement including the cap domain.
Alternatively an acidified solvent water molecule might donate a proton to the substrate. In the second
step of the reaction cycle the covalent intermediate hydrolyses via a nucleophilic attack by a D11
activated solvent water on the phosphorus atom.
Due to the instability of the intermediate state, the phosphorylation pathway of enzymes from the
HAD superfamily that utilise aspartate as the catalytic nucleophile has been difficult to study. Our
findings support a mechanism that is in line with the catalytic scaffold described for HAD
phosphotransferases and proves an involvement of D11 in dephosphorylation. The sEH phosphatase
belongs to the HAD class I subfamily of phosphotransferases that contain a small cap domain and
therefore are prone to small phosphate substrates17; 27. The enzyme has been shown to accept lipid
phosphates as substrates and therefore a role of the phosphatase domain in lipid metabolism was
suggested. Still, the physiological function of the sEH phosphatase activity is not resolved and with
regards to the diversity in substrate acceptance within the HAD superfamily it seems possible that the
sEH might also play a different role. Whereas prokaryotic HAD are mainly involved in the
metabolism of small substrates, HADs from higher organisms show a broader spectrum of larger
substrates like proteins53. On the other hand other HADs are thought to accept phosphorylated
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substrates from both classes35. Interestingly, this was also shown for a tyrosine phosphatase, the tumor
suppressor PTEN that can act on both polypeptide and phosphoinositide substrates54.
In view of phosphorylation events that are often key steps in regulatory processes, the phosphatase
activity may likely regulate the sEH epoxide hydrolase function in balancing levels of lipid mediators,
which leaves a rich area for further investigation to enlighten the physiological interplay of these two
sEH activities.
Experimental procedures
Cloning, expression and purification of recombinant sEH in E.coli
The expression plasmid pGEF-HisC-sEH-Nterm encoding for the N-terminal 221 amino acids of
the human sEH phosphatase domain containing a C-terminal His-Tag was constructed as described
earlier 12; 55. For production of recombinant enzymes E. coli BL21-AI bacterial cells (Invitrogen) were
transformed with the resulting constructs and grown in LB medium containing 100 µg/ml ampicillin.
At an OD600 of 0.5 protein expression was induced with 100 µM L-arabinose and cells were grown at
room temperature overnight. Bacterial cultures were harvested by centrifugation at 3,000 g and 4°C
for 10 min. Pellets were resuspended in ammonium hydrogencarbonate buffer, pH 7.8 in 1/10 of the
culture volume and cells were broken by one pass through a FrenchPress (Thermo Scientific,
Waltham, MA, USA) pressure cell at 30,000 psi. The resulting lysates were cleared by centrifugation
at 10,000 g and 4°C for 20 min. The His-tagged sEH phosphatase was purified on HisTrap chelating
HP columns (GE Healthcare, Freiburg, Germany) in 20 mM phosphate, 500 mM NaCl, pH 7.4 using
an elution gradient from 0-500 mM imidazole, according to the manufacturer’s instructions. sEH
phosphatase containing fractions were pooled, concentrated by ultrafiltration in VivaSpin2 columns
(Sartorius, Göttingen, Germany) and further purified on a Superdex 200 size exclusion column (GE
Healthcare, Uppsala, Sweden) in 20 mM Hepes, 50 mM NaCl, pH 7.4. sEH phosphatase containing
fractions were analysed by SDS-PAGE and used for further analysis.
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Production of active site mutants
Active site mutants of the human sEH phosphatase were produced using the site directed
mutagenesis Kit from Stratagene (La Jolla, CA, USA) according to the manufacturer’s instructions. In
order to simplify the identification of correct mutants, the primers used for introduction of the different
point mutations also carried additional or modified restriction sites. Recombinant clones were isolated
and verified both by restriction and sequence analysis to ensure the correctness of the encoded amino
acid sequence. The resulting expression plasmids coding for active site mutants of the human sEH
phosphatase were transformed in competent E. coli BL21-AI bacterial cells, and the expression and
purification of the recombinant proteins was performed as described above.
Activity assay procedure
Phosphatase activity of the sEH was measured using 4-nitrophenyl phosphate as substrate by
following the formation of 4-nitrophenol in a continuous assay at 405 nm in a Spectramax 250
microplate reader (Molecular Devices, Ismaning, Germany). Typically, 5-20 µg purified enzyme were
added to a mixture of 0.1 - 6.4 mM 4-nitrophenyl phosphate in a buffer containing 50 mM Tris-HCl,
50 mM NaCl, 10 mM MgCl2 at pH 7.8 in a final volume of 250 µl. Product formation was followed at
37°C for 30 min, and analysed at conditions where the product formation rate remained constant over
time. Activity measurements were performed in triplicate from three separately produced and purified
protein batches. Kinetic constants were calculated by plotting the reciprocal velocity against reciprocal
substrate concentration.
Preparation of tryptic peptides of native sEH
Typically 10-50 µg purified native WT or mutant sEH protein was digested with 5 ng/ml trypsin in
digestion buffer (10 mM ammonium hydrogencarbonate, 10% acetonitrile , 0.01% Triton X-100, pH
8.0) in a total volume of 100 µl for 3 hrs at 37°C. The tryptic digests were adjusted to a final
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concentration of 0.1% acetic acid. Samples were centrifuged for 2 min at 13.000 rpm, filtered through
a 0.45 µm regenerated cellulose filter (Infochroma AG, Zug, Switzerland) and directly analysed by
LC-MS/MS or stored at -20°C.
Phosphorylation and derivatisation of sEH with sodium borohydride
Typically 50 µg of purified WT or mutant sEH protein was incubated in 20 mM ammonium
hydrogencarbonate buffer, 50 mM NaCl, 10 mM MgCl2, pH 7.8 in a total volume of 100 µl with 2
mM 4-nitrophenyl phosphate for 10 min at 37°C. Sodium borohydride was added to a final
concentration of 5 mM from a stock solution of 200 mM sodium borohydride in DMSO and further
incubated for 10 min at RT. Proteins were precipitated with 4 volumes of acetone containing 5 mM
sodium borohydride, incubated at -20°C for 45 min and pelleted for 10 min at 13.000 rpm and 4°C.
Control reactions were performed without addition of sodium borohydride at any stage. The protein
pellets were washed with acetone, briefly dried, reconstituted in a solution of 5 ng/ml trypsin in
digestion buffer and processed as described above.
18O Incorporation
For potential 18O incorporation 10-50 µg of purified WT sEH were incubated in 20 mM ammonium
hydrogencarbonate buffer, 10 mM NaCl, 10 mM MgCl2 pH 8.0 solved in 75% 18H2O in a total volume
of 100 µl with 2 mM 4-nitrophenyl phosphate for 15 min at 37°C. The resulting assay mixture was
directly digested with trypsin and processed as described above.
LC-MS/MS Analysis of tryptic sEH peptides
The resulting peptides mixtures were separated on a Agilent 1100 liquid chromatography system
using a Agilent ZORBAX 300SB-C18 narrow bore reversed phase column (2.1 µm x 150 mm, 5 µm
pore size) with a corresponding ZORBAX 300 SB guard-column. The mobile phase consisted of (A)
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0.1% formic acid and (B) acetonitrile containing 0.1% formic acid, using a flow rate of 170 µl/min and
an injection volume of 10 µl. Starting conditions of 2% buffer B were maintained for 5 min, followed
by a linear gradient from 2 to 100% B within 45 min. An isocratic flow of 100% B was applied for 5
min and finally the column was re-equilibrated for 10 min with 2% B. The HPLC system was coupled
to a 4000 QTrap hybrid quadrupole linear ion trap mass spectrometer (Applied Biosystems) equipped
with a TurboV source and electrospray (ESI) interface. For the selective identification of sEH
peptides, the QTrap system was configured to detect specific transitions in a MRM initiated detection
and sequencing (MIDAS) workflow using multiple reaction monitoring (MRM) in the positive mode
with the following source specific parameters: IS 5000V, TEM 450°C, curtain gas = 20 (CUR),
nebulizer gas = 40 (GS1), heater gas = 50 (GS2) and collision gas = 10 (CAD). For detection of sEH
peptides a list of MRM transitions was generated either by manual calculation or by the Applied
Biosystems MIDAS software. Transitions were included for tryptic peptides (maximum one missed
cleavage) including the WT and mutated or modified species, and for single to triply charged species
for the Q1 mass range 400-2000 m/z using calculated collision energies (CE) and a dwell time of
14ms for each MRM transition to ensure analysis during the peak elution time. In the triple quadrupole
scan function the precursor ions were selected by the first quadrupole set with a unit mass window.
Using an information dependant acquisition (IDA) workflow, the mass spectrometer was switched to
an enhanced product ion (EPI) scan mode, when an individual MRM signal exceeded 200 counts. All
MRM transitions were measured sequentially with the cycle time of 4.55 s looped throughout the
length of the HPLC separation. Enhanced product ion scanning was carried out using parameters
detailed in the supplemental data. Fragment spectra were matched against an NCBI protein sequence
database using the Mascot search engine (Matrix Science Ltd.). All Mascot searches were performed
species specific, with trypsin plus one missed cleavage, a peptide tolerance of 1.2 Da, a MS/MS
tolerance 0.5 Da, allowing error tolerant searches. In addition, data were examined manually using the
features of the Analyst 1.4.2 software package.
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Figure and Table Legends
Table 1. Kinetic parameters for WT and mutant sEH proteins. Mutant sEH proteins were expressed, 
purified and analysed as described in the experimental section using 4-nitrophenyl phosphate (4-NPP) 
as a substrate for activity determination in a photometric assay. The standard deviation is given for at 
least three independent measurements from separately purified protein batches. Kinetic constants were 
calculated by plotting the reciprocal velocity against reciprocal substrate concentration in a 
Lineveawer Burk representation. ND = not detectable; detection limit was determined to 1 
nmol/mg/min. ! mark significant changes in Km (two sided student t-test) compared to the WT enzyme 
(D11N: P-value 0.016, N124D: P-value 0.016). 
Fig. 1. Domain structure and catalysis of human sEH. (a) Domain structure of homodimeric human 
soluble epoxide hydrolase composed of a C-terminal epoxide hydrolase and an N-terminal 
phosphatase domain. The cap- and core-domains of the phosphatase HAD subunit including the four 
loops presenting the conserved active site residues are highlighted. The structure representation was
prepared using the program PyMOL (DeLano Scientific LLC, San Carlos, CA, USA, v9.07) based on 
the coordinates from PDB data file 1VJ536. (b) The C-terminal domain acts as an epoxide hydrolase on 
xenobiotic as well as arachidonic acid derived epoxides to form the corresponding diols. The N-
terminal domain instead acts as a phosphatase on generic and lipid derived phosphates. (c) Stereo view 
of the structure model of the phosphatase active site containing Mg2+ and HPO42- in the complex, 
prepared using the program PyMOL based on the coordinates from PDB data file 1VJ5. The amino 
acid side chains forming the sEH phosphatase active site are depicted in the stick representation.
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Fig. 2. Structure based sequence alignment of human sEH and other HAD members. Structure based
sequence alignment of human sEH with haloacid dehalogenase from Pseudomonas sp. (HAD),
phosphonoacetaldehyde hydrolase from Bacillus cereus (Phos), and phosphoserine phosphatase from
Methanococcus janaschii (PSP). The positions of catalytic residues in the designated conserved motifs
according to four loops adapted from Morais et al.30 are indicated in red and with arrows, partly
conserved residues are indicated in green. The numbers of connecting residues for each segment are
given.
Fig. 3. Expression and purification of human sEH active site mutants in E.coli. (a) The expression
plasmids for the production of different sEH phosphatase active site mutants containing a C-terminal
His6-Tag were constructed as described in the experimental section. The amino acid residues selected
for site directed mutagenesis of the phosphatase active site are indicated in the sEH open reading
frame. The expression cassette is under the control of the T7 promoter. (c) SDS-PAGE analysis of
purified WT and mutant human sEH phosphatase proteins after purification on metal chelate and size
exclusion chromatography. The picture shows purified sEH WT phosphatase as well as mutants D9N
and D185N and N189D as representative examples. Proteins were separated on denaturing 12% (w/v)
polyacrylamide gel, coomassie stained and compared to a molecular weight standard.
Fig. 4. MS/MS analysis of the sEH D185N mutant for potential deamination. (a) and (b) show the
fragment ion spectra of the precursor ions 1050.062+ and 1049.62+ corresponding to the sEH WT and
mutant D185N peptide - as specified in the panel respectively - following extended incubation for a
potential deamination of asparagine. The mutation is clearly detected in the fragment ion spectrum of
the D185N peptide (b), because the y-ions 10 and greater show a mass difference of 1 amu compared
to the WT peptide, which corresponds to the amino acid exchange in position 185 in the tryptic
peptide. An analysis using the Mascot search engine also significantly detects the D185N point
mutation when using an error tolerant search.
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Fig. 5. Detection of the site of sEH phosphorylation after reduction with sodium borohydride by
LC-MS/MS. Panel (a) shows the protein sequence of the human sEH phosphatase domain as produced
using the recombinant expression system corresponding to 227 amino acids. Tryptic peptides covered
in the MRM method are highlighted in bold letters and the D9 containing peptide is underlined. The
phosphatase active site amino acids are presented in italic and the phosphorylation site during the
active cycle is marked. The amino acid sequence of the WT peptide with the corresponding series of
y- and b- ions generated after fragmentation is further presented in panel (a). Panel (b) and (c) show
total ion chromatograms (TIC) of detected peptides, derived from the D11N mutant and the WT sEH
respectively. The peak at 32.7 min in WT sEH - which shifts to 32.5 min due to an exchange of D to N
in the untreated mutants D9N or D11N - looses intensity and an additional double peak with a
maximum at 32.02 min appears which matches the retention time of the 1043.12+ precursor ion -
corresponding to the hSer-modified peptide.  Panels (d) and (e) show the MS/MS fragment ion spectra
of the precursor ions 1050.62+ and 1043.12+ corresponding to the WT peptide and the D11N peptide
containing an additional mutation D9hS as specified in the panel, respectively. The precursor ion mass
difference corresponds to an exchange of aspartic acid against homoserine after reduction of the
phosphorylated proteins with sodium borohydrid, whereas the y-ion series from 9-14 identify both
sEH peptides. Diagnostic fragments to identify the D9hS mutated peptides are marked with arrows.
Fig. 6. Enzymatic mechanism of phosphate hydrolysis. In the first step of the catalytic cycle of
dephosphorylation the active site nucleophile D9 attacks the substrate phosphorous under formation of
a covalent enzyme acylphosphate and release of the hydrolysed substrate as described in the
discussion section. In a second step a water molecule that is activated via proton abstraction by D11
leads to hydrolysis of the enzyme phosphate intermediate and regeneration of the enzyme.
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Table 1
Enzyme Km Vmax kcat kcat/Km
(mM) (nmol-1 mg-1 min) (s-1) (M-1 s-1)
WT 1.11 ± 0.13 69.8 ± 15.4 0.030 ± 0.007 27.80 ± 8.61
D9A ND ND ND      ND
D9N ND ND ND      ND 
D11A ND ND ND      ND
D11N 0.57 ± 0.04! 8.1 ± 4.8 0.002 ± 0.004 6.14 ± 3.46
T123A 1.07 ± 0.39 5.0 ± 3.7 0.002 ± 0.002 1.96 ± 0.71
T123N 0.91 ± 0.29 1.9 ± 1.1 0.001 ± 0.001 1.02 ± 0.45
T123V ND ND ND      ND
N124A 1.05 ± 0.30 4.0 ± 2.7 0.002 ± 0.001 1.71 ± 0.94
N124D 2.48 ± 0.40! 5.7 ± 2.2 0.002 ± 0.001 1.05 ± 0.58
K160R ND ND ND      ND
K160N ND ND ND      ND
K160A ND ND ND      ND
D184N ND ND ND      ND
D184A ND ND ND      ND
D185A ND ND ND      ND
D185N 1.56 ± 0.42 27.4 ± 20.1 0.012 ± 0.009 7.13 ± 3.93
N189A ND ND ND      ND
N189D ND ND ND      ND 
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